Peter Welford
Stock Analyst at Jefferies
(1.67)
# 3,167
Out of 4,749 analysts
13
Total ratings
40%
Success rate
2.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Welford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK | Downgrades: Hold | n/a | $35.27 | - | 3 | Nov 12, 2024 | |
| NVS Novartis AG | Downgrades: Hold | n/a | $104.72 | - | 2 | Sep 3, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $70.76 | - | 4 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $23.00 | +105.22% | 3 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $19.67 | - | 1 | Sep 16, 2021 |
GSK
Nov 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $35.27
Upside: -
Novartis AG
Sep 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $104.72
Upside: -
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $70.76
Upside: -
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $23.00
Upside: +105.22%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $19.67
Upside: -